Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-VV400 With Rapamycin in Relapsed or Refractory B-cell Malignancies
NCT07735533Phase 2Recruiting
- Sponsor
- Umoja Biopharma
- Start
- Sep 2026
- Primary completion
- Aug 2031
- Countries
- 1
01
Overview
A Phase 2 trial of UB-VV400/410 in diffuse large B-cell lymphoma (DLBCL), sponsored by Umoja Biopharma. Started Sep 2026; status: recruiting.
02
Drugs
UB-VV400/410
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07735533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735533.